Roche adds expertise through leadership appointments

Appoints new leaders in the company’s Oncology and Specialty Medicines Clusters

Appoings Jinyoung Jeong as Lead of Oncology·Hematology Cluster

Appoints Hyunmi Kim as Lead of Specialty Medicines Cluster

With the goal to solidify the company’s leadership in the areas of Oncology and Specialty medicines

(from the left) Jinyoung Jeong, Lead of Oncology·Hematology Cluster, and Hyunmi Kim, Lead of Specialty Medicines Cluster

Roche Korea is strengthening its leadership by appointing new leads to its Oncology and Hematology cluster and Specialty Medicines cluster.

 

The company announced on the 5th that it has appointed Jinyoung Jeong as the new head of the Oncology·Hematology Cluster and Hyun-mi Kim as the new head of the Specialty Medicines Cluster.

 

By appointing two new leaders with extensive industry experience and expertise, Roche Korea plans to strengthen its portfolio across various therapeutic areas, including solid and hematological tumors, ophthalmic diseases, and neurological diseases, and solidify its innovative medicine leadership.

 

Jinyoung Jeong graduated from the College of Pharmacy at Seoul National University and has accumulated experience in pharmaceutical marketing at Mundipharma Korea and Pfizer Korea since 2009.

 

Prior to her new role, she was the Lead of the Lung Cancer Diseases Area in Roche APAC, where Jeong played a leading role in designing organizational operations and portfolio strategies and maximizing synergies by strengthening cross-country collaboration.

 

Hyun-mi Kim first entered the pharmaceutical industry in 2004 when she joined Janssen Korea after graduating from the College of Pharmacy at Seoul National University and earning a master's degree from the same university.

 

Since then, Kim has led business growth in a wide range of fields, including blood cancer, solid cancer, immunology, and neuroscience, and has demonstrated her ability to plan business strategies and develop new businesses in global markets, including Korea, the United States, China, and the Asia-Pacific (APAC) region.

 

Jinyoung Jeong, Lead of Oncology·Hematology Cluster at Roche Korea, said, “Based on the experience and expertise I have accumulated in Oncology at Roche Korea, I will take the lead to promptly provide innovative treatment solutions to Korean patients suffering from cancer.

 

We will continue to prioritize the extension of patients’ lives and improvement of their quality of life, and focus on expanding treatment access.” Hyun-mi Kim, Lead of the Specialty Medicines Cluster at Roche Korea, said “I am pleased to join Roche Korea, which has been driving innovation in the industry as a a global pharmaceutical industry leader.

 

In the Specialty Medicines area, which includes ophthalmic and neurological diseases, it is very important to address unmet patient needs and reduce the burden of disease through innovation.

 

I will make every effort to help more patients lead healthy and happy lives.”